| Revenue growth | FY26 growth 3% YoY; Q4 grew 2% YoY. |
|---|---|
| Margins | FY26 EBITDA margin 25%; FY27 guided to mid-20s. |
| Order book | Extension of BMS partnership to 2035 provides long-term visibility. |
| Demand visibility | Strong interest in Unit 3 biologics and ADC discovery lab. |
| Management confidence | Confident in long-term momentum despite near-term Librela and leadership transitions. |
Growth
FY26 revenue up 3% YoY; Q4 revenue INR 1,037 Cr (up 2% YoY, 13% QoQ). FY26 PAT before exceptions down 20%.
Outlook
FY27 revenue guidance flat YoY; growth weighted to H2. Targeting strategic reset for stronger growth from FY28 onwards.
Risks
Continued Librela destocking impact through H1 FY27; geopolitical uncertainties; high staff and utility costs from new facilities.
Earnings Call filed with NSE, NSE: SYNGENE. Summary written with AI assistance from the document.
Syngene International Ltd: key numbers
- Share price
- ₹378.70
- Market cap
- ₹15,287 Cr
- Revenue (annual)
- ₹3,739 Cr
- Net profit (annual)
- ₹316.7 Cr
- P/E (TTM)
- 69.2×Sector 50.4×
- Promoter holding
- 52.59%-0.09% QoQ
- FII holding
- 11.82%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Syngene International Ltd
All →Syngene International Management Change
Syngene International Limited announced the resignation of Mr. Pramuch Goel, Head of Corporate Affairs & Communications and Senior Management Personnel, effective September 21, 2026.
Syngene International Other Announcement
Syngene International Limited has issued a communication to shareholders regarding the remittance of the final dividend for the financial year 2025-26.
Syngene International Investor Presentation: Key Takeaways
Syngene reports Q1 FY27 revenue of Rs 736 Cr (-16% YoY). Performance was impacted by low offtake from a major client and forex losses.
Syngene International Q1 FY27 Results: Net Loss of ₹9 Cr
Syngene International Ltd reported revenue from operations of ₹736 Cr (-15.8% YoY) and a net loss of ₹9 Cr for Q1 FY27.
- Key figure
- Net loss ₹9 Cr
Syngene International Earnings Call: Key Takeaways
Syngene faces a transition year in FY27 as the Librela de-stocking headwind masks underlying momentum in biologics and research services.
Syngene International Earnings Call: Key Takeaways
Syngene Q4 FY26 revenue grew 2% YoY to Rs 1,037 Cr with 29% EBITDA margin. Full year FY26 revenue reached Rs 3,739 Cr, driven by integrated CRDMO services.